New Advances in the Treatment for Small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.06.05
- Author:
Xiaoxia CUI
1
;
Peng SONG
1
;
Li ZHANG
1
Author Information
1. Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Antiangiogenic agents;
Biology;
Immune checkpoint inhibitors;
Lung neoplasms;
Molecular-target therapy
- MeSH:
Angiogenesis Inhibitors;
administration & dosage;
Animals;
Humans;
Immunologic Factors;
administration & dosage;
Immunotherapy;
Lung Neoplasms;
diagnosis;
drug therapy;
Small Cell Lung Carcinoma;
diagnosis;
drug therapy
- From:
Chinese Journal of Lung Cancer
2019;22(6):355-362
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is a refractory cancer with high degree of malignancy, rapid disease progression, poor prognosis and easy recurrence. In the past 30 years, the traditional treatment of SCLC, mainly chemotherapy and radiotherapy, has not changed significantly, and the effective treatment method for clinical needs is extremely urgent. The rapid development of precision medicine has revealed the molecular biological characteristics of SCLC, so its diagnosis and treatment will into a new era. At present, some studies have shown that anti-angiogenic drugs, immunotherapy and so on have improved the efficacy of SCLC treatment to some extent, and there are more studies on the diagnosis and treatment of SCLC, so a new field of SCLC treatment are coming and bringing more survival benefits to patients. New studies on targeted therapy, anti-angiogenesis drugs and immunotherapy of molecular pathology of SCLC are emerging. This paper reviews the new diagnosis and treatment methods of SCLC to provide new guidance for its clinical treatment.
.
